Results from study with Episealer® Knee implant accepted for presentation at German orthopaedic congress
Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Knee preservation of the middle-aged patient - two-staged treatment combination of patient specific metal implant and osteotomy. A case series.”, by Priv.-Doz. Dr. med. Clemens Kösters, has been accepted for presentation at the 11th annual congress of the Deutschen Kniegesellschaft (DKG, the German Knee Society). The congress will take place in Munich, Germany, on November 18-19, 2022.
The abstract reports on the clinical outcome for patients having undergone a two-stage treatment with a combination of Episurf Medical’s personalised knee implant Episealer®, and knee osteotomy, for treatment of chondral and osteochondral defects in the knee, at Maria-Josef-Hospital, Greven, Germany.
“We appreciate the continued interested in the clinical outcome for patients treated with our Episealer® Knee implants. This specific study is highly interesting as it is the first study with follow-up of patients who have undergone a combination of joint preserving treatment alternatives, potentially allowing treatment of more severe defects than each of the interventions alone could have treated”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: